Chemical giant Bayer to cut management jobs after huge loss

Chemical giant Bayer to cut management jobs after huge loss

Bayer brought in a new CEO this year to steer the company in a new direction after a series of problems
Bayer brought in a new CEO this year to steer the company in a new direction after a series of problems. Photo: INA FASSBENDER / AFP/File
Source: AFP

German chemicals giant Bayer said Wednesday it would cut management jobs and was examining splitting off one of its divisions after reporting a massive third-quarter loss.

The maker of Aspirin has long been under pressure from activist investors as its problems mounted, and earlier this year brought in a new CEO to help steer the company in a new direction.

It reported a net loss nearly 4.6 billion euros ($4.9 billion) from July to September, compared to a profit of nearly 550 million euros in the same period last year, dragged down by massive writedowns at its agrochemicals division.

This was linked to losses related to higher interest rates, and also reflects ongoing problems in the division due to falling sales and prices of its key glyphosate-based herbicides.

"We're not happy with this year's performance," new chief executive Bill Anderson said in a statement.

Read also

Global wine production hits lowest level since 1961

The company said it plans "remove multiple layers of management and coordination" by the end of the year, which will include "a significant reduction in the workforce".

PAY ATTENTION: Share your outstanding story with our editors! Please reach us through info@corp.legit.ng!

Bayer did not say how many jobs might be affected.

"95 percent of the decision-making in the organisation will shift from managers to the people doing the work," said Anderson.

The diversified group -- whose products include medicines, seeds and crop chemicals -- said it was looking at splitting off either its consumer health or crop science division.

Splitting the company into three businesses had been examined, but ruled out, it said.

Further details will be disclosed in March, it said. Splitting the company into at least two parts -- the agricultural and pharmaceutical businesses -- to contain problems has been a key demand of investors.

Bayer has faced problems since its 2018 takeover of US firm Monsanto.

Read also

Angry Qantas investors block executives' pay plan

The German conglomerate inherited Monsanto's legal woes around its Roundup glyphosate-based weedkiller, and has since faced a wave of lawsuits in the United States over claims it causes cancer.

Bayer denies this.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.